$IONS

Ionis Pharmaceuticals (IONS) reported positive Phase 3 results for two drugs, sefaxersen and ulefnersen, despite a 44% YTD stock decline. The company's fair value is estimated at $88, suggesting a 49% undervaluation. Revenue growth and pipeline progress are cited as potential drivers, though regulatory and pricing risks remain.

Ionis Pharmaceuticals (IONS) reported positive Phase 3 trial results for two RNA-targeted drugs: sefaxersen, partnered with Roche, met its primary endpoint in IgA nephropathy, and ulefnersen, developed with Otsuka, achieved its main goal in FUS-ALS. These results could expand Ionis's market share and revenue, but pricing and regulatory risks remain.

Novartis' Phase 3 trial for Pelacarsen showed it lowered lipoprotein(a) but failed to reduce major cardiovascular events. Citi suggests this may influence CRISPR Therapeutics' focus on CTX321 over CTX320, while Ionis Pharmaceuticals may see limited impact. Citi maintains Buy ratings for both companies with price targets of $88 for CRISPR and $100 for Ionis.

Ionis Pharmaceuticals (IONS) stock hit a 52-week low of $44.20, trading at $44.24 with a $7.39B market cap. The stock has fallen 30.81% over the past year and 42% year-to-date. Analysts have mixed views, with price targets ranging from $54 to $105. Recent clinical trial results showed positive outcomes for Ulefnersen in FUS-ALS, but some analysts lowered price targets due to concerns about drug launches and trial results.

BMO Capital reiterated a Market Perform rating and $54 price target for Ionis Pharmaceuticals (IONS) after positive ALS drug trial results. The stock is near its 52-week low, down 42% YTD. The study met primary endpoints, showing functional improvement and survival benefits. Analysts have mixed outlooks, with some lowering price targets due to recent setbacks.

Roche and Ionis Pharmaceuticals reported positive Phase 3 trial results for sefaxersen, their RNA therapy for kidney disease, meeting the primary endpoint of reducing proteinuria. The drug showed a statistically significant improvement in urine protein-to-creatinine ratio compared to placebo, suggesting potential for accelerated FDA approval. Ionis' CEO indicated a regulatory filing would follow soon.

Ionis Pharmaceuticals (IONS) and Roche (RHHBY) reported positive late-stage trial results for their kidney drug sefaxersen, meeting its primary endpoint based on interim data. The therapy is designed for patients with primary IgA nephropathy, a kidney disorder.

Ionis Pharmaceuticals and Roche reported positive Phase 3 trial results for sefaxersen, an IgA nephropathy treatment. The trial met its primary endpoint, showing significant proteinuria reduction at 37 weeks. Sefaxersen showed a consistent safety profile. The trial will continue to assess long-term kidney function. Roche's licensing deal includes past and potential future payments, reinforcing Ionis's strategic position.

IONIS PHARMACEUTICALS INC (IONS) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN) – Sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class po

Otsuka Pharmaceutical and Ionis Pharmaceuticals reported that their experimental drug, ulefnersen, met the primary endpoint in a late-stage study for FUS-ALS, a rare inherited form of ALS. The drug improved function and survival compared to placebo, with a favorable safety profile. The companies plan to discuss the results with the FDA and other health authorities for potential accelerated approval. Otsuka also launched a global early access program for eligible patients.